Nothing Special   »   [go: up one dir, main page]

FR23C1038I2 - Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b - Google Patents

Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b

Info

Publication number
FR23C1038I2
FR23C1038I2 FR23C1038C FR23C1038C FR23C1038I2 FR 23C1038 I2 FR23C1038 I2 FR 23C1038I2 FR 23C1038 C FR23C1038 C FR 23C1038C FR 23C1038 C FR23C1038 C FR 23C1038C FR 23C1038 I2 FR23C1038 I2 FR 23C1038I2
Authority
FR
France
Prior art keywords
directed against
antibody directed
against type
cytotoxic antibody
proliferations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1038C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of FR23C1038I1 publication Critical patent/FR23C1038I1/fr
Application granted granted Critical
Publication of FR23C1038I2 publication Critical patent/FR23C1038I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR23C1038C 2004-12-15 2023-10-20 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b Active FR23C1038I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0413320A FR2879204B1 (fr) 2004-12-15 2004-12-15 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
PCT/FR2005/003123 WO2006064121A2 (fr) 2004-12-15 2005-12-14 Anticorps cytotoxique dirige contre les proliferations hematopoïetiques lymphoïdes de type b

Publications (2)

Publication Number Publication Date
FR23C1038I1 FR23C1038I1 (fr) 2023-12-08
FR23C1038I2 true FR23C1038I2 (fr) 2024-05-03

Family

ID=34953790

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0413320A Active FR2879204B1 (fr) 2004-12-15 2004-12-15 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR23C1038C Active FR23C1038I2 (fr) 2004-12-15 2023-10-20 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0413320A Active FR2879204B1 (fr) 2004-12-15 2004-12-15 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.

Country Status (15)

Country Link
US (2) US9234045B2 (fr)
EP (2) EP1824887B1 (fr)
JP (2) JP4999699B2 (fr)
KR (3) KR101340192B1 (fr)
CN (1) CN101115772B (fr)
AU (1) AU2005315534B2 (fr)
BR (1) BRPI0519044B8 (fr)
CA (1) CA2590303C (fr)
DK (1) DK1824887T3 (fr)
ES (1) ES2588161T3 (fr)
FR (2) FR2879204B1 (fr)
IL (1) IL183947A0 (fr)
NL (1) NL301242I2 (fr)
PL (1) PL1824887T3 (fr)
WO (1) WO2006064121A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
WO2006082428A2 (fr) 2005-02-03 2006-08-10 Topotarget Uk Limited Polytherapies faisant appel a des inhibiteurs de hdac
PT1901729E (pt) 2005-05-13 2012-04-30 Topotarget Uk Ltd Formulações farmacêuticas de inibidores de hdac
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
EP1957056A2 (fr) 2005-11-10 2008-08-20 TopoTarget UK Limited Inhibiteurs d'histone desacetylase (hdac) pour le traitement du cancer
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1985633A1 (fr) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit de parties pour le traitement du cancer ou de maladies infectueuses
CN101868446A (zh) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
MX2010011057A (es) 2008-04-11 2010-11-12 Trubion Pharmaceuticals Inc Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
FR2940616A1 (fr) * 2008-12-30 2010-07-02 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire.
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
FR2962908A1 (fr) * 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
FR2966043A1 (fr) * 2010-10-14 2012-04-20 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cerebral primitif
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP2537864B1 (fr) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Variantes Fc dotées de fonctions effectrices réduites
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
CN104884095A (zh) * 2012-07-13 2015-09-02 宾夕法尼亚大学董事会 Cart19用于耗减正常b细胞以诱导耐受的用途
EP3150256B1 (fr) * 2012-11-02 2020-07-15 TG Therapeutics Inc. Combinaison d'anticorps anti-cd20 et inhibiteur sélectif pi3 kinase
CN109640964A (zh) 2016-05-27 2019-04-16 Tg治疗有限公司 用于治疗B细胞增殖性紊乱的抗-CD20抗体、P13激酶-δ选择性抑制剂和BTK抑制剂的组合
CA3035976A1 (fr) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combinaison d'un anticorps anti-cd20, d'un inhibiteur de pi3 kinase-delta et d'un anticorps anti-pd-1 ou anti-pd-l1 pour le traitement de cancers hematologiques
WO2022104150A1 (fr) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combinaison pour traiter des malignités des lymphocytes b
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752248B1 (fr) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à differentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
PT981637E (pt) * 1997-03-14 2005-09-30 Biogen Idec Inc Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1383800A4 (fr) 2001-04-02 2004-09-22 Idec Pharma Corp Anticorps recombinants co-exprimes avec gntiii
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
CA2481657A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules a genome modifie
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP2092939A3 (fr) * 2002-09-13 2011-12-21 LFB Biotechnologies Utilisation thérapeutique d'anticorps induisant la production de cytokines
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
DE60332957D1 (de) * 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
CN1542132A (zh) 2003-04-30 2004-11-03 上海新霁生物科技有限公司 高效表达治疗肿瘤并含有人恒定区全抗体基因的重组病毒及其用途
WO2005063815A2 (fr) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.

Also Published As

Publication number Publication date
BRPI0519044A2 (pt) 2008-12-23
FR23C1038I1 (fr) 2023-12-08
FR2879204B1 (fr) 2007-02-16
WO2006064121A3 (fr) 2006-08-31
AU2005315534B2 (en) 2011-11-10
CN101115772A (zh) 2008-01-30
IL183947A0 (en) 2007-10-31
US9873745B2 (en) 2018-01-23
NL301242I2 (nl) 2023-11-01
KR20070102513A (ko) 2007-10-18
AU2005315534A1 (en) 2006-06-22
DK1824887T3 (en) 2016-09-05
KR101418695B1 (ko) 2014-07-10
CN101115772B (zh) 2012-10-17
US20090053233A1 (en) 2009-02-26
EP2949674A1 (fr) 2015-12-02
JP2012126724A (ja) 2012-07-05
KR20120023177A (ko) 2012-03-12
EP1824887A2 (fr) 2007-08-29
JP5693440B2 (ja) 2015-04-01
JP4999699B2 (ja) 2012-08-15
BRPI0519044B1 (pt) 2020-11-17
JP2008523793A (ja) 2008-07-10
BRPI0519044B8 (pt) 2021-05-25
CA2590303A1 (fr) 2006-06-22
CA2590303C (fr) 2015-05-26
KR20140003660A (ko) 2014-01-09
WO2006064121A2 (fr) 2006-06-22
US9234045B2 (en) 2016-01-12
EP1824887B1 (fr) 2016-05-25
US20160060350A1 (en) 2016-03-03
FR2879204A1 (fr) 2006-06-16
ES2588161T3 (es) 2016-10-31
PL1824887T3 (pl) 2016-12-30
KR101340192B1 (ko) 2013-12-12
NL301242I1 (nl) 2023-09-20

Similar Documents

Publication Publication Date Title
FR23C1038I2 (fr) Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
ATE527262T1 (de) Neue tomaymycin derivate enhaltende zytotoxische mittel
IL189876A0 (en) Pharmaceutical formulations containing anti-cd3 antibody
NO20075628L (no) Farmasøytiske formuleringer
HK1114568A1 (en) Stable protein formulations
IL188733A0 (en) Immunoconjugate formulations
ZA200902772B (en) Liquid anti-rabies antibody formulations
ATE469058T1 (de) Zigarettenpackung
DE602004023367D1 (de) Modulare Achsanordnung
DE112005002927A5 (de) Mehrkammerverpackung
FR2887530B1 (fr) Ensemble de conditionnement et de distribution
ITMI20060108A1 (it) Dispsotivo avvolgitore
BRPI0613691A2 (pt) bico de enchimento
DK1900812T3 (da) Lipase-pulversammensætning
ZA200800146B (en) Immunoconjugate formulations
IL191150A0 (en) Cytotoxic antibodies targeting antibodies inhibiting factor viii
ES1061423Y (es) Cenicero perfeccionado
ES1059080Y (es) Envase dispensador de productos celulosicos y similares.
ES1061537Y (es) Cenicero
ITTO20050140U1 (it) Portacenere
FR2881050B1 (fr) Dcchol chez les nouveaux-nes
UA10548S (uk) Упакування для сигарет «classic»
UA13550S (uk) Обгортка
UA12066S (uk) Обгортка